[
serum institute of india
]
Serum Institute joins hands with CII to accelerate vaccination in rural areas
By hindustantimes.com | Written by Harshit Sabarwal | Edited by Poulomi Ghosh, New Delhi
UPDATED ON JUL 30, 2021 06:00 PM IST
Speaking on Friday’s development, SII’s chief executive officer (CEO) Adar Poonawalla said the partnership with the Confederation of Indian Industry “will be a good way to close the gaps” as there is plenty of supply of Covishield doses available for distribution.
News updates from HT: IMD says monsoon revival unlikely before July 7
By hindustantimes.com, Hindustan Times, New Delhi
PUBLISHED ON JUL 01, 2021 08:50 AM IST
- Here are today’s top news, analysis, and opinion at this hour. Know all about the latest news and other news updates from Hindustan Times.
Jolt to Serum Institute as govt panel says no to Covovax trial on children
By hindustantimes.com | Written by Amit Chaturvedi, Hindustan Times, New Delhi
PUBLISHED ON JUL 01, 2021 07:01 AM IST
The clinical trials of Covovax began in India in March. But the Subject Expert Committee of the Central Drugs Standard Control Organisation denied the approval for its trial on children noting that the vaccine has not been approved in any country.
SII applies for EU ‘green pass’ nod through UK partner
By Rhythma Kaul, Hindustan Times, New Delhi
UPDATED ON JUL 01, 2021 06:16 AM IST
The Green Pass is an immunity document meant to ease travel within and to the European Union from July 1. “The EMA certification has been applied for by SII via its partner AstraZeneca,” said an industry insider familiar with the matter, on condition of anonymity.
SII says working on Covishield EU pass
By HT Correspondent, Hindustan Times, New Delhi
UPDATED ON JUN 29, 2021 04:41 AM IST
Indian officials said it was “perplexing” that the list includes Vaxzevria, the AstraZeneca vaccine produced and marketed in the UK and other sites around Europe, but not Covishield, the version manufactured and distributed in India, though they are similar if not identical.
‘Great potential’: Serum Institute begins production of 1st Covovax batch
Agencies | By HT Correspondent, Hindustan Times, New Delhi
PUBLISHED ON JUN 26, 2021 04:27 AM IST
US biotechnology company Novavax’s protein-based vaccine, NVX-CoV2373, has demonstrated 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial.
Serum Institute of India likely to start Covovax trials on kids by July
By Rhythma Kaul, New Delhi
PUBLISHED ON JUN 18, 2021 05:26 AM IST
- The trials could start by July, one of the people added on the condition of anonymity.
Biological E’s vaccine efficacy same as Novavax: Government panel chief
By Rhythma Kaul, New Delhi
UPDATED ON JUN 18, 2021 07:00 AM IST
- Earlier this month, the Union health ministry announced that it had finalised arrangements with the Hyderabad-based vaccine manufacturer to reserve 300 million doses
SII to introduce Novavax vaccine in India by September: Report
Written by Shankhyaneel Sarkar | Edited by Poulomi Ghosh, Hindustan Times, New Delhi
PUBLISHED ON JUN 17, 2021 05:01 PM IST
- Novavax vaccine has shown strong efficacy against the emerging variants of Covid-19 in a large trial, the biotech firm said on June 14.
Shortage of raw material holding up Covovax manufacturing
By Divya Rajagopal, New Delhi
UPDATED ON JUN 17, 2021 07:55 AM IST
- The delay in receiving raw materials such as bioreactor bags and enzymes means that SII’s launch of the Novavax vaccine, branded as Covovax in India, will not likely happen before September this year as planned originally
SII gets DCGI’s nod to manufacture Sputnik
By Rhythma Kaul, Hindustan Times, New Delhi
UPDATED ON JUN 05, 2021 03:48 AM IST
Sputnik V is currently being distributed in India by Dr Reddy’s Laboratories, which signed a pact with the Russian Direct Investment Fund (RDIF), which globally markets the Covid-19 vaccine developed by Russia’s Gamaleya Institute.
News updates from HT: Maharashtra records 14,152 new cases of Covid-19 in 24 hrs
By hindustantimes.com, Hindustan Times, New Delhi
PUBLISHED ON JUN 04, 2021 09:32 PM IST
- Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.
DCGI allows Serum Institute to manufacture Sputnik V vaccine in India
By hindustantimes.com | Written by Joydeep Bose
PUBLISHED ON JUN 04, 2021 09:10 PM IST
The Pune-based SII has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, in Russia for developing Sputnik V at its licensed Hadapsar facility.
Serum Institute of India applies to DCGI to manufacture Covid vaccine Sputnik V
By hindustantimes.com | Edited by Amit Chaturvedi, Hindustan Times, New Delhi
PUBLISHED ON JUN 03, 2021 12:18 PM IST
Sputnik V is the third Covid-19 vaccine to be approved by India's drugs regulator DCGI after Bharat Biotech's Covaxin and Covishield, which is manufactured by Serum Institute of India (SII).
Can manufacture, supply 90-100 million Covishield doses in June: SII to govt
By hindustantimes.com | Written by Meenakshi Ray, New Delhi
PUBLISHED ON MAY 30, 2021 06:17 PM IST
SII informed the Centre earlier in May that the production of Covishield would be ramped up to 65 million in June, 70 million in July and 100 million each in August and September.
Centre creating 'artificial scarcity' to favour SII, Bharat Biotech, says AAP
By hindustantimes.com | Edited by Ayshee Bhaduri, Hindustan Times, New Delhi
PUBLISHED ON MAY 28, 2021 04:56 PM IST
- AAP spokesperson Atishi claimed that neither Bharat Biotech nor SII possesses the capacity to mass manufacture the required number of vaccine doses to inoculate the entire population of the country.
Serum Institute of India begins production of Covovax vaccine
By HT Correspondent, New Delhi
PUBLISHED ON MAY 27, 2021 02:47 AM IST
US biotechnology company Novavax’s protein-based Covid-19 vaccine, NVX-CoV2373, is being locally manufactured by SII under the brand name Covovax.
‘Daily cases were at an all-time low’: Poonawalla defends India’s vaccine export
By hindustantimes.com | Written by Kunal Gaurav | Edited by Avik Roy, Hindustan Times, New Delhi
PUBLISHED ON MAY 18, 2021 08:35 PM IST
- Serum Institute of India (SII) CEO Adar Poonawalla said the company exported Covid-19 vaccines when health experts believed that the country was “turning the tide on the pandemic.”
The Taste with Vir Sanghvi: The dream of a modern India is dying
By Vir Sanghvi
UPDATED ON MAY 06, 2021 01:21 PM IST
- In this week's The Taste, Vir Sanghvi writes, "Such is the despondency over our politicians that many people are now actively considering emigrating to other countries"
Poonawallas turned down $1 billion offer from private equity firms
By Deborshi Chaki, Mumbai
UPDATED ON MAY 05, 2021 06:27 AM IST
- The Poonawalla family-owned firm turned down the offer by a consortium of private equity firm TPG Capital, Abu Dhabi’s ADQ and Saudi Arabia’s Public Investment Fund following differences over valuation
UK PM announces new £1 bn trade deal with India
By Rezaul H Laskar, New Delhi
PUBLISHED ON MAY 04, 2021 03:21 AM IST
- The package contains new Indian investments of more than £533 million that is expected to create more than 6,000 jobs in vital sectors such as health and technology.
Under pressure from powerful to give jabs: Adar Poonawalla
By HT Correspondent, New Delhi
UPDATED ON MAY 02, 2021 12:52 AM IST
The pressure was what led him to fly to London to be with his wife and children, Poonawalla, 40, told British newspaper The Times in an interview
'Everything falls on my shoulders': Adar Poonawalla on vaccine pressure in India
PTI | | Posted by Prashasti Singh, London
PUBLISHED ON MAY 01, 2021 06:37 PM IST
“I’m staying here (London) for an extended time because I don't want to go back to that situation. Everything falls on my shoulders but I can't do it alone...,” Poonawalla said.
Serum Institute CEO plans to start Covid-19 vaccine production abroad: Report
Reuters |
UPDATED ON MAY 01, 2021 06:05 AM IST
"There's going to be an announcement in the next few days," Serum Institute of India CEO Adar Poonawalla said.
Short of doses, Delhi to keep expanded jabs drive on hold
PUBLISHED ON APR 30, 2021 04:05 AM IST
Of the 13.4 million doses needed by the Capital, Delhi will get the first batch of 300,000 shots only by May 3 from Serum Institute of India (SII), which manufactures Covishield, the mainstay of India’s vaccination programme, senior officials aware of developments said.
SII reduces vaccine price for state govts
By Rhythma Kaul
PUBLISHED ON APR 29, 2021 02:34 AM IST
SII, which manufactures the vaccine developed by Oxford University and British drug firm AstraZeneca, had last week announced a price of ₹400 for states and ₹600 for private hospitals to purchase jabs for the third phase.
'We remember India's generosity': US vows to deliver vaccine resources
By hindustantimes.com | Written by Joydeep Bose | Edited by Avik Roy
PUBLISHED ON APR 27, 2021 01:23 PM IST
"What we are doing is diverting our own order of our own supplies to the Serum Institute for their manufacturing," a senior administration official said, elaborating on the exact nature of the assistance that the US is providing to India in view of the recent Covid-19 surge.
India's close allies US, UAE and Saudi Arabia step forward in Covid fight
By Shishir Gupta, New Delhi
PUBLISHED ON APR 26, 2021 08:54 AM IST
While National Security Advisor Ajit Doval spoke to his US counterpart Jake Sullivan, Saudi and UAE royals, foreign minister Jaishankar has been in constant touch with Secretary of State Anthony Blinken and his European counterparts for bridging the health infrastructural gap in India.
Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin
PTI | , New Delhi
PUBLISHED ON APR 25, 2021 04:45 PM IST
- In support of their proposal, Bharat Biotech has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf-life.
Adar Poonawalla has assured 'maximum support': CMO Maharashtra on vaccination
Written by Prashasti Singh, Hindustan Times, New Delhi
PUBLISHED ON APR 25, 2021 09:05 AM IST
Maharashtra is the worst-hit state in the country with 6,94,480 active cases of the coronavirus disease (Covid-19).